ClinicalTrials.gg
CompletedNCT04880213Updated Apr 6, 2022

Study of M5049 in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of M5049 and M5049 in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate and determine the safety, tolerability and pharmacokinetics of single-doses of M5049 up to 3 dose levels administered as film-coated tablet under fasted conditions in healthy Japanese and Caucasian participants.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • M5049
  • Japanese
  • Caucasian
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants must be first generation (born in Japan) with both biological parents and all 4 biological grandparents being Japanese native born. Caucasian participants must have both biological parents and 4 biological grandparents of Caucasian descent
  • Overtly healthy participants as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring (blood pressure, heart rate and 12-Lead resting )
  • Participants with body weight within 45 to 90 kilograms (kg) (female) and 55 to 90 kg (male) and (BMI) between 18.5 and 29.9 kilograms per meter square (kg/m\^2)
  • A Caucasian participant will be matched by body weight (± 20% body weight [kg]), height (± 15% height [centimeter (cm) ]) and sex to each Japanese participant
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with history of disease of any organ system that may interfere with the objectives of the study or provide a risk to the health of the participant
  • Participants with history of relevant drug
  • Participants with history of splenectomy, epilepsy, other neurological disorders or neuropsychiatric conditions
  • Participants with history of a tuberculosis and positive Screening test for surface antigen
  • Participants with history of alcoholism or drug abuse
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Japanese: M5049 Dose A (low dose)

    Drug: M5049

  • Experimental
    Japanese: M5049 Dose B (medium dose)

    Drug: M5049

  • Experimental
    Japanese: M5049 Dose C (high dose)

    Drug: M5049

  • Experimental
    Caucasian: M5049 Dose A (low dose)

    Drug: M5049

  • Experimental
    Caucasian: M5049 Dose B (medium dose)

    Drug: M5049

  • Experimental
    Caucasian: M5049 Dose C (high dose)

    Drug: M5049

Interventions

  • DrugM5049

    Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.

  • DrugM5049

    Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.

  • DrugM5049

    Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (tlast) (AUC0-tlast) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  2. Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  4. Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death

    Time frame: Baseline up to Day 8

  5. Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters

    Time frame: Baseline up to Day 3

  6. Number of Participants with Clinically Significant Changes from Baseline in Vital Signs

    Time frame: Baseline up to Day 3

  7. Number of Participants with Clinically Significant Changes from Baseline in 12-lead Electrocardiogram (ECGs) Findings

    Time frame: Baseline up to Day 3

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to 48 Hours Post-dose (AUC0-48) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  2. Time to Reach Maximum Plasma Concentration (tmax) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  3. Terminal Half-life (t1/2) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  4. Apparent Total Body Clearance (CL/f) of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

  5. Apparent Volume of Distribution (Vz/f) During Terminal Phase of M5049

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose

07

Study locations

1 site
  • Covance Clinical Research Unit Ltd.
    Leeds, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Nov 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2021
First posted
May 10, 2021
StartActual
May 6, 2021
Primary completionActual
Nov 23, 2021
CompletionActual
Nov 23, 2021
Last update
Apr 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04880213
Responsible party
Sponsor
First posted
May 10, 2021
Start date
May 6, 2021
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Last update
Apr 6, 2022

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enpatoran

Start the discussion